Details of the Drug-Related molecule(s) Interaction Atlas

General Information of DTT (ID: TTL4Q97)

• DTT Name: Cyclin-dependent kinase 5 (CDK5) DTT Info
• UniProt ID: CDK5_HUMAN
• Gene Name: CDK5

Molecule-Related Drug & Molecule List

8 Patented Agent(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
4-(thiazol-5-yl)-pyrimidine derivative 2	DMMQFCN	N. A.	N. A.	Patented	[1]
Flavonoid derivative 7	DM6A9UR	N. A.	N. A.	Patented	[1]
KENPAULLONE	DMAGVXW	Discovery agent	N.A.	Patented	[2]
Naphthyridine and isoquinoline derivative 1	DMTGIP7	N. A.	N. A.	Patented	[1]
PMID26161698-Compound-18	DM6JVR5	N. A.	N. A.	Patented	[1]
Pyrazolo[1,5-a]-1,3,5-triazine derivative 1	DMOK7CW	N. A.	N. A.	Patented	[1]
Roscovitine derivative 1	DMD1G3Z	N. A.	N. A.	Patented	[1]
Tricyclic benzimidazole derivative 1	DM5SD9E	N. A.	N. A.	Patented	[1]

1 Preclinical Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
L-751250	DMOERXK	Obesity	5B81	Preclinical	[3]

1 Discontinued Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Olomoucine	DMNAFG1	N. A.	N. A.	Terminated	[3]

16 Investigative Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
1-phenyl-3-(2-(pyridin-4-yl)thiazol-4-yl)urea	DMJVITG	Discovery agent	N.A.	Investigative	[4]
10Z-Hymenialdisine	DMIRSA5	Discovery agent	N.A.	Investigative	[3]
3-(2-phenylthiazol-4-yl)quinolin-2(1H)-one	DMQC9WV	Discovery agent	N.A.	Investigative	[5]
9-Nitropaullone	DM8LUYM	Discovery agent	N.A.	Investigative	[3]
aloisine A	DM5U1LN	Discovery agent	N.A.	Investigative	[6], [7]
aminopurvalanol A	DMKLC3O	N. A.	N. A.	Investigative	[8]
AZAKENPAULLONE	DM61H07	Discovery agent	N.A.	Investigative	[2]
Indirubin-3'-monoxime	DMLRQH0	Discovery agent	N.A.	Investigative	[3]
Indirubin-5-sulfonate	DM08VHZ	Discovery agent	N.A.	Investigative	[3]
MANZAMINE A	DMB3GNC	Discovery agent	N.A.	Investigative	[9]
NU6140	DMCUSG3	Discovery agent	N.A.	Investigative	[10]
Oxindole 16 (compound 3)	DMM5208	Discovery agent	N.A.	Investigative	[3]
Oxindole 95	DM4UL1G	Discovery agent	N.A.	Investigative	[3]
Quinoxaline1	DMRWXH4	Discovery agent	N.A.	Investigative	[8]
SU9516	DMQHG0R	Discovery agent	N.A.	Investigative	[3]
Thieno analogue of kenpaullone	DMIOTHG	Discovery agent	N.A.	Investigative	[2]

References

• [1] Cyclin-dependent kinase inhibitors for cancer therapy: a patent review (2009 - 2014).Expert Opin Ther Pat. 2015;25(9):953-70.
• [2] 1-Azakenpaullone is a selective inhibitor of glycogen synthase kinase-3 beta. Bioorg Med Chem Lett. 2004 Jan 19;14(2):413-6.
• [3] Pharmacological inhibitors of cyclin-dependent kinases. Trends Pharmacol Sci. 2002 Sep;23(9):417-25.
• [4] Structure-activity relationships of 3,4-dihydro-1H-quinazolin-2-one derivatives as potential CDK5 inhibitors. Bioorg Med Chem. 2007 Oct 15;15(20):6574-95.
• [5] Design and synthesis of quinolin-2(1H)-one derivatives as potent CDK5 inhibitors. Bioorg Med Chem Lett. 2007 Oct 1;17(19):5384-9.
• [6] Aloisines, a new family of CDK/GSK-3 inhibitors. SAR study, crystal structure in complex with CDK2, enzyme selectivity, and cellular effects. J Med Chem. 2003 Jan 16;46(2):222-36.
• [7] The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
• [8] A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases. Proc Natl Acad Sci U S A. 2007 Dec 18;104(51):20523-8.
• [9] Glycogen synthase kinase-3 (GSK-3) inhibitory activity and structure-activity relationship (SAR) studies of the manzamine alkaloids. Potential for ... J Nat Prod. 2007 Sep;70(9):1397-405.
• [10] Potentiation of paclitaxel-induced apoptosis by the novel cyclin-dependent kinase inhibitor NU6140: a possible role for survivin down-regulation. Mol Cancer Ther. 2005 Sep;4(9):1328-37.